|
Apr 2
|
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
|
|
Apr 2
|
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
|
|
Apr 2
|
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
|
|
Mar 26
|
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
|
|
Mar 21
|
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
|
|
Mar 18
|
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
|
|
Mar 18
|
J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use
|
|
Mar 13
|
Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study
|
|
Mar 8
|
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
|
|
Mar 7
|
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
|
|
Mar 7
|
Chairman of Vanda Pharmaceuticals Inc (VNDA) Sells Shares
|
|
Mar 6
|
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
|
|
Mar 6
|
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
|
|
Mar 5
|
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
|
|
Mar 4
|
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
|
|
Feb 29
|
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
|
|
Feb 29
|
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
|
|
Feb 27
|
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
|
|
Feb 23
|
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
|
|
Jan 12
|
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
|